X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
VENUS REMEDIES Fact Sheet, VENUS REMEDIES Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Fact Sheet   (VSRM)

Here is the latest financial fact sheet of VENUS REMEDIES. For more details, see the VENUS REMEDIES quarterly results and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

VENUS REMEDIES Price History

Price Rs 39.1
Mkt Cap Rs m 447
Vol '000 10.1
P/E X -3.3
P/CF X 14.2
EPS (TTM) Rs -11.7
% ch % -2.0
No. of shares m 11.44
% ch week % 9.7
% ch 1-mth % -30.4
% ch 12-mth % -62.1
52 week H/L Rs 125.9/34.6
(As on Oct 17, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

VENUS REMEDIES Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
VENUS REMEDIES EQUITY SHARE DATA
High Rs358330218143126 
Low Rs140103826561 
Sales per share (Unadj.) Rs473.4405.6365.6324.2301.8 
Earnings per share (Unadj.) Rs56.24.51.5-13.8-24.9 
Diluted earnings per shareRs56.24.51.5-14.9-26.8 
Cash flow per share (Unadj.) Rs91.444.737.918.82.5 
Dividends per share (Unadj.) Rs00000 
Adj. dividends per shareRs0.000.000.000.000.00 
Dividend yield (eoy) %00000 
Book value per share (Unadj.) Rs403.5399.2382.5315.0293.3 
Adj. book value per shareRs403.5399.2382.5339.7316.4 
Shares outstanding (eoy) m11.4411.4411.4412.3412.34 
Bonus/Rights/Conversions  WC---- 
Price / Sales ratio x0.50.50.40.30.3 
Avg P/E ratio x4.447.9101.0-7.5-3.8 
P/CF ratio (eoy) x2.74.84.05.536.7 
Price / Book Value ratio x0.60.50.40.30.3 
Dividend payout %00000 
Avg Mkt Cap Rs m2,8492,4711,7171,2821,154 
No. of employees `000NANA1.00.90.9 
Total wages/salary Rs m305324250343393 
Avg. sales/employee Rs ThNMNM4,100.74,430.14,026.1 
Avg. wages/employee Rs ThNMNM245.3379.5425.0 
Avg. net profit/employee Rs ThNMNM16.7-189.1-331.8 
VENUS REMEDIES INCOME DATA
Net Sales Rs m5,4164,6404,1834,0003,724 
Other income Rs m57202323 
Total revenues Rs m5,4204,6474,2034,0233,747 
Gross profit Rs m1,382892812507395 
Depreciation Rs m402460417403338 
Interest Rs m294412380344354 
Profit before tax Rs m6912735-216-275 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m48-2518-4632 
Profit after tax Rs m6435217-171-307 
Gross profit margin %25.519.219.412.710.6 
Effective tax rate %6.9-94.851.621.1-11.5 
Net profit margin %11.91.10.4-4.3-8.2 
VENUS REMEDIES BALANCE SHEET DATA
Current assets Rs m2,7212,6752,7592,5942,638 
Current liabilities Rs m2,1101,9651,9201,9682,305 
Net working cap to sales %11.315.320.115.68.9 
Current ratio x1.31.41.41.31.1 
Inventory Days Days96112125128135 
Debtors Days Days4450544346 
Net fixed assets Rs m5,0735,2195,2885,0564,871 
Share capital Rs m114114114123123 
"Free" reserves Rs m4,4504,4453,8833,7633,496 
Net worth Rs m4,6164,5674,3763,8873,619 
Long term debt Rs m1,4001,6861,9111,6181,374 
Total assets Rs m8,3448,4118,0477,6507,509 
Interest coverage x3.31.11.10.40.2 
Debt to equity ratio x0.30.40.40.40.4 
Sales to assets ratio x0.60.60.50.50.5 
Return on assets %11.25.54.92.30.6 
Return on equity %13.91.10.4-4.4-8.5 
Return on capital %16.47.06.62.31.6 
Exports to sales %00000 
Imports to sales %17.017.720.518.413.9 
Exports (fob) Rs m00000 
Imports (cif) Rs m921821858736517 
Fx inflow Rs m00000 
Fx outflow Rs m921822858736517 
Net fx Rs m-921-822-858-736-517 
VENUS REMEDIES CASH FLOW
From Operations Rs m 527 678 469 589 514 
From Investments Rs m -947 -672 29 -183 -123 
From Financial Activity Rs m 401 -14 -464 -441 -387 
Net Cashflow Rs m -20 -8 35 -35 4 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 32.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.2%
FIIs 0.6%
ADR/GDR 0.0%
Free float 66.4%
Shareholders 20,121
Pledged promoter(s) holding 36.4%
 

Company Information

REGD OFF SCO 857, 2nd Floor, Cabin No. 10, NAC Manimajra, Chandigarh-160 101
E-MAIL investorgrievance@venusremedies.com WEB www.venusremedies.com
TELEPHONE (0172) 393 3094 FAX (0172) 256 5566
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, A-31, Naraina Indl. Area, Phase 1, New Delhi-28
AUDITOR J. K. Jain & Assoc.
CHM: Pawan Chaudhary (MD) COMP SEC: Neha Kodan YEAR OF INC: 1989 BSE CODE: 526953 FV (Rs): 10 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   PFIZER  NATCO PHARMA  FULFORD INDIA  STRIDES SHASUN LTD  MERCK LTD  

Compare VENUS REMEDIES With:   PFIZER  NATCO PHARMA  FULFORD INDIA  STRIDES SHASUN LTD  MERCK LTD  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Views on news

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ALKEM LABORATORIES COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS